S1 Table. Inclusion and exclusion criteria

Inclusion criteria

1. Cancer patient who will receive high emetogenic chemotherapeutic agents according to the NCCN guideline for antiemesis version 2.2014
2. Patients ≥ 19 years old
3. ECOG performance status 0-2
4. Available for oral administration
5. Patients with normal range of plasma K, Mg, and Ca
6. Patients with below 450 msec of QT interval (EKG Screening); Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion criteria

1. Severe hypertension, severe heart disease, congenital long QT syndrome or bradyarrhythmia disease, Kidney disease, liver disease
2. Patients with GI obstruction or other diseases that could provoke nausea and vomiting
3. Patients who haven nausea and vomiting within 1 week before chemotherapy
4. Patients who should take steroid, antiemetics, pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine, phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir for the treatment of other diseases; Patients with symptomatic brain metastasis
5. Patients receiving chemotherapy within 12 months before enrollment
6. Patients receiving radiation therapy during study period
7. Patients receiving radiation therapy within 2 weeks before chemotherapy
8. Patients who have known allergy or severe side effect on study drugs
9. Pregnant or lactating women, or women who wish to become pregnant
10. Others whom the investigator judges inappropriate as subjects for this study

NCCN, National Comprehensive Cancer Network.